500 results on '"Wort, Stephen"'
Search Results
2. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry
3. Survival outcomes in EIF2AK4 mutation-associated pulmonary arterial hypertension: seeking clarity in contrast.
4. Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology
5. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.
6. Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
7. Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement
8. Right ventricular dysfunction in critically ill COVID-19 ARDS
9. Neurological complications in aortic coarctation: Results of a Nationwide analysis based on 11,907 patients
10. Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?
11. A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study
12. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension
13. Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
14. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
15. Incidence, mortality and bleeding rates associated with pulmonary embolism in England between 1997 and 2015
16. Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
17. A rare presentation of pulmonary hypertension
18. Corrigendum to “Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology” [Int J Cardiol Congenit Heart Dis, Volume 7, March 2022, 100331]
19. Sarcoidosis associated pulmonary hypertension: an update
20. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension
21. Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry
22. Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.
23. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry
24. An autocrine role for endogenous endothelin-1 released from human pulmonary artery smooth muscle implications for the pathogenesis of pulmonary hypertension
25. Molecular Biological Aspects, Therapeutic Targets and New Treatment Strategies
26. Determinants of outpatient clinic attendance amongst adults with congenital heart disease and outcome
27. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension
28. Pulmonary hemodynamics and transplant-free survival in sarcoidosis-associated pulmonary hypertension:Results from an international registry
29. Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension
30. Physiological differences between various types of Eisenmenger syndrome and relation to outcome
31. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
32. miR‐322‐5p targets IGF‐1 and is suppressed in the heart of rats with pulmonary hypertension
33. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements
34. First Genotype-Phenotype Study in TBX4 Syndrome: Gain-of-Function Mutations Causative for Lung Disease
35. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study
36. Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome
37. Disease targeting therapies in patients with Eisenmenger syndrome: Response to treatment and long-term efficiency
38. Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome
39. British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations
40. Pulmonary arteriovenous malformations emerge from the shadows
41. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension
42. Abstract 14753: Loss of Function ABCC8 Mutations Are Associated With Pulmonary Arterial Hypertension
43. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension
44. Cardiac remodelling amongst adults with various aetiologies of pulmonary arterial hypertension including Eisenmenger syndrome—implications on survival and the role of right ventricular transverse strain
45. Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy
46. Response by Kempny et al to Letter Regarding Article, “Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study”
47. Pulmonary hypertension in left heart disease: A review
48. A framework of deep learning networks provides expert-level accuracy for the detection and prognostication of pulmonary arterial hypertension
49. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
50. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.